Emergency Department-Initiated Buprenorphine Validation Network Trial

Opioid-use Disorder Clinical Trial

Official title:

Emergency Department-Initiated Buprenorphine Validation Network Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04225598
• Other study ID #: 2000026164
• Secondary ID: 2UG1DA015831-19
• Status: Recruiting
• Phase: Phase 2
• Start date: July 8, 2020
• Est. completion date: July 31, 2024

Study information

• Verified date: December 2023
• Source: Yale University
• Contact: Gail D'Onofrio, MD, MS
• Phone: 203-785-7059
• Email: gail.donofrio[@]yale.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will (1) recruit, train and provide resources to approximately 30 Emergency Department (ED) sites throughout the U.S. using implementation facilitation strategies to provide ED-initiated buprenorphine (BUP) for patients presenting with opioid use disorder (OUD) who are not receiving medications for opioid use disorder (MOUD). Once implementation is adequately achieved, the sites will (2) conduct a randomized controlled trial (RCT) to compare the effectiveness of sublingual buprenorphine (SL-BUP) versus extended-release buprenorphine (XR-BUP) on ED patients' engagement in formal addiction treatment 7-days after their ED visit. In addition, in an ancillary component of the study, the investigators will (3) assess the use of XR-BUP in ED patients with Clinical Opioid Withdrawal Scale (COWS) scores < 8 in a case series to potentially expand the eligibility of patients in the larger RCT to those presenting with little to no opioid withdrawal symptoms. Finally, the investigators will (4) develop and validate ED electronic health record (EHR) opioid-related phenotypes, both of which will inform the main RCT.

Description:

The study will be comprised of four components as outlined below: 1. Site implementation component: In this component, the investigators will use previously developed implementation facilitation strategies and resources to train ED providers and staff at approximately 30 diverse EDs in treatment initiation with SL-BUP and XR-BUP and develop ED buprenorphine protocols and procedures. The investigators anticipate that this will result in a minimum of 24 sites (80%) that will meet the implementation milestones for competence in ED-initiated BUP using standard SL and XR-BUP inductions. 2. Effectiveness RCT component: This component is a large pragmatic RCT using a Hybrid Type 1 Effectiveness-Implementation design. Sites that satisfactorily complete the site implementation component will be activated on a rolling basis for the RCT after demonstrated implementation milestones have been met. In this Hybrid Type 1 design the primary research question is the effectiveness of SL-BUP induction compared with that of XR-BUP on the primary outcome measure of engagement in formal addiction treatment at 7-days post ED visit. This design also allows us to gather information and report on implementation processes. 3. Ancillary component - XR-BUP Induction for patients with COWS < 8: This observational case series will begin in advance of the Effectiveness RCT component at approximately 4 ED sites with extensive experience in ED-initiated BUP. The investigators will collect quantitative and qualitative data on the use of XR-BUP in ED patients with low COWS scores for approximately 75 patients. Sites will receive a supply of XR-BUP for provision to up to 5 patients with a COWS score > 8. The purpose is to pre-study the procedures at the four ancillary study sites on treating OUD patients with XR-BUP prior to initiation of the ancillary component. Data collected from this pre-study will not be included in the analysis of the ancillary and effectiveness RCT component. These initial up to 20 pre-study patients will meet all other study criteria and undergo all assessments. It is anticipated that the information collected from the 75 patients in the ancillary component will allow for modification to the larger Effectiveness RCT by expanding eligibility criteria to include patients with COWS <8. 4. Development and validation of EHR ED opioid-related phenotypes component: In this component, the investigators will develop EHR phenotypes of opioid-related illnesses that accurately and automatically characterize patient conditions, enhance the ability to actively monitor and surveil, and better identify representative samples and patients potentially eligible for study inclusion, leading ultimately to an enhanced inclusion and understanding of opioid-related conditions. At the primary Yale New Haven Health System sites, the phenotypes (rules- and machine learning-based) will be iteratively developed and internally validated. The rules-based phenotype will be mapped to a common data model and externally validated at 4 trial sites. 5. An exploratory outcome of this study will be to assess the impact of COVID-19 on ED use for opioid-related diagnoses using EHR data. The primary focus of this clinicaltrials.gov registration are the RCT outcomes. Implementation and ancillary outcomes will be identified as secondary outcomes for the purpose of this clinicaltrials.gov registration

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: July 31, 2024
• Est. primary completion date: July 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

RCT Component:

Inclusion Criteria:

1. Be 18 years or older

2. Treated in the ED during study screening hours

3. Meet DSM-5 (Diagnostic and Statistical Manual) diagnostic criteria for moderate to severe OUD

4. Have a COWS score of > or equal to 4

5. Have a urine toxicology test that is positive for opioids (opiates, oxycodone, buprenorphine). Patients with urines that are only positive for fentanyl will be eligible if their clinical history and physical exam are consistent with opioid use and they meet DSM-5 criteria for moderate to severe OUD.

6. Able to speak English sufficiently to understand the study the study procedures and provide written informed consent to participate in the study. (Exception may be made if sites with large population of Spanish speaking patients are accepted for participation in the study and study materials are translated into Spanish. Translated study materials will be reviewed and approved by the Institutional Review Board) IRB of record prior to use.)

Exclusion Criteria:

1. Have urine toxicology test that is positive for methadone

2. Be pregnant as determined by human chorionic gonadotropin (hCG) testing at the index ED visit

3. Have a medical or psychiatric condition that requires hospitalization

4. Opioid administration (excluding BUP) at the index ED visit, prior to enrollment, and COWS remains < 8 during ED stay

5. Be actively suicidal or severely cognitively impaired precluding informed consent

6. Present from an extended care facility (e.g., skilled nursing facility)

7. Require continued prescription opioids for a pain condition

8. Be a prisoner or in police custody at the time of index ED visit

9. Be currently (anytime within the past 14 days) enrolled in formal addiction treatment, including by court order. Patients enrolled in formal addiction who are not receiving MOUD are eligible

10. Be unable to provide reliable locator information including 2 contact numbers in addition to their own

11. Be unwilling to follow study procedures (e.g., unwilling to provide permission to contact referral provider/program or unavailable for the follow-up assessments)

12. Have prior enrollment in the current study component Ancillary Component:

Inclusion Criteria:

1. Be 18 years or older

2. Treated in the ED during study screening hours

3. Meet DSM-5 diagnostic criteria for moderate to severe opioid use disorder

4. Have a COWS <8

5. Have a urine toxicology test that is positive for opioids (opiates, oxycodone, or buprenorphine). Patients with urines that are only positive for fentanyl on the point of care test strip will be eligible if their clinical history and physical exam are consistent with opioid use and they meet DSM-5 criteria for moderate to severe OUD.

6. Be able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study

Exclusion Criteria:

1. Have a urine toxicology test that is positive for methadone

2. Be pregnant as determined by human chorionic gonadotropin (hCG) testing at the index ED visit

3. Have a medical or psychiatric condition that requires hospitalization at the index ED visit, prior to enrollment

4. Be actively suicidal or severely cognitively impaired precluding informed consent

5. Present from an extended care facility (e.g., skilled nursing facility)

6. Require continued prescription opioids for a pain condition

7. Be a prisoner or in police custody at the time of index ED visit

8. Be currently (anytime within the past 7 days) enrolled in formal addiction treatment, including by court order. Patients enrolled in formal addiction treatment but are not receiving MOUD are eligible

9. Be unable to provide reliable locator information including 2 contact numbers in addition to their own

10. Be unwilling to follow study procedures (e.g., unwilling to provide permission to answer daily assessments until day 7)

11. Have prior enrollment in the current study

Related Conditions & MeSH terms

• Emergencies
• Opioid-Related Disorders
• Opioid-use Disorder

Intervention

Drug:
• CAM2038
Patients will receive a 24 mg dose of injectable CAM2038 in the ED on Day 0.
• Buprenorphine Sublingual Product
COWS = 8: Patients will receive 4mg of SL-BUP for a COWS score of 8-12 (mild withdrawal). After 30-45 minutes if tolerated and no unanticipated adverse reactions, an additional 4mg can be administered for a total of 8mg in the ED. Patients presenting with moderate-severe withdrawal (COWS >= 13) will receive an initial dose of 8mg SL-BUP. All patients will receive a buprenorphine prescription and instructions for additional BUP doses to allow for up to a dose of 12mg if needed, and for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD (medications for opioid use disorder). COWS 4-7: Patients will be provided with a uniform set of instructions to guide unobserved (home) induction. They will be prescribed doses of SL-BUP to allow them to take dose up to 12mg in the 24 hours after discharge. All patients will also receive a buprenorphine prescription for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD.

Locations

Country	Name	City	State
United States	Presybterian Hospital, Albuquerque, NM	Albuquerque	New Mexico
United States	University of New Mexico Hospital	Albuquerque	New Mexico
United States	Grady Memorial Hospital	Atlanta	Georgia
United States	Johns Hopkins Hospital	Baltimore	Maryland
United States	Cooper University Hospital	Camden	New Jersey
United States	Medical University of South Carolina	Charleston	South Carolina
United States	Northwestern Memorial Hospital	Chicago	Illinois
United States	University of Chicago Medicine	Chicago	Illinois
United States	Parkland Memorial Hospital	Dallas	Texas
United States	Detroit Receiving Hospital	Detroit	Michigan
United States	Henry Ford Hospital	Detroit	Michigan
United States	Duke University	Durham	North Carolina
United States	Dartmouth-Hitchcock Medical Center	Lebanon	New Hampshire
United States	West Virginia University - Berkeley Medical Center	Martinsburg	West Virginia
United States	Jackson Memorial Hospital	Miami	Florida
United States	Hennepin County Medical Center	Minneapolis	Minnesota
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	Yale New Haven Health (Yale New Haven Hospital)	New Haven	Connecticut
United States	Bellevue Hospital	New York	New York
United States	Columbia University Irving Medical Center- NY Presbyterian	New York	New York
United States	Icahn School of Medicine	New York	New York
United States	Weill Cornell Medical College	New York	New York
United States	Highland Hospital	Oakland	California
United States	Pennsylvania Presbyterian Medical Center/Hospital of UPENN	Philadelphia	Pennsylvania
United States	Temple University Hospital - Episcopal Campus	Philadelphia	Pennsylvania
United States	Valleywise Health	Phoenix	Arizona
United States	UPMC Mercy Hospital	Pittsburgh	Pennsylvania
United States	Maine Medical Center	Portland	Maine
United States	Rhode Island Hospital/The Miriam Hospital	Providence	Rhode Island
United States	Barnes Jewish Hospital	Saint Louis	Missouri
United States	University of Utah Hospital	Salt Lake City	Utah
United States	San Leandro Hospital	San Leandro	California
United States	University of Washington Medical Center- Harborview/Montlake	Seattle	Washington
United States	Upstate Medical University	Syracuse	New York
United States	Tampa General Hospital	Tampa	Florida
United States	Wake Forest School of Medicine	Winston-Salem	North Carolina

Sponsors (10)

Lead Sponsor	Collaborator
Yale University	Alameda Health System, Harvard Medical School (HMS and HSDM), Icahn School of Medicine at Mount Sinai, National Drug Abuse Treatment Clinical Trials Network, National Institute on Drug Abuse (NIDA), NYU Langone Health, The Emmes Company, LLC, University of Pennsylvania, Weill Medical College of Cornell University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	RCT Component: Cost effectiveness of XR-BUP compared to SL-BUP using ICER (incremental cost-effectiveness ratio): Engagement	The final outcome measure for the cost-effectiveness analysis is the ICER (incremental cost-effectiveness ratio), which includes the relevant cost differential between the study arms in the numerator, and the difference in a chosen effectiveness measure in the denominator. 3 types of ICERs will be generated, each one with a different effectiveness measure (engagement in formal addiction treatment at 30 days; quality-adjusted life-years (QALYs) gained; and Abstinent Years). The reason being that different ICERs are more relevant to certain potential stakeholder groups than others.	7 days post randomization
Other	RCT Component: Cost effectiveness of XR-BUP compared to SL-BUP using ICER (incremental cost-effectiveness ratio): QALYs	The final outcome measure for the cost-effectiveness analysis is the ICER (incremental cost-effectiveness ratio), which includes the relevant cost differential between the study arms in the numerator, and the difference in a chosen effectiveness measure in the denominator. 3 types of ICERs will be generated, each one with a different effectiveness measure (engagement in formal addiction treatment at 30 days; quality-adjusted life-years (QALYs) gained; and Abstinent Years). The reason being that different ICERs are more relevant to certain potential stakeholder groups than others.	7 days post randomization
Other	RCT Component: Cost effectiveness of XR-BUP compared to SL-BUP using ICER (incremental cost-effectiveness ratio): Abstinent Years	The final outcome measure for the cost-effectiveness analysis is the ICER (incremental cost-effectiveness ratio), which includes the relevant cost differential between the study arms in the numerator, and the difference in a chosen effectiveness measure in the denominator. 3 types of ICERs will be generated, each one with a different effectiveness measure (engagement in formal addiction treatment at 30 days; quality-adjusted life-years (QALYs) gained; and Abstinent Years). The reason being that different ICERs are more relevant to certain potential stakeholder groups than others.	7 days post randomization
Other	RCT Component: Cost effectiveness of XR-BUP compared to SL-BUP using ICER (incremental cost-effectiveness ratio): Engagement	The final outcome measure for the cost-effectiveness analysis is the ICER (incremental cost-effectiveness ratio), which includes the relevant cost differential between the study arms in the numerator, and the difference in a chosen effectiveness measure in the denominator. 3 types of ICERs will be generated, each one with a different effectiveness measure (engagement in formal addiction treatment at 30 days; quality-adjusted life-years (QALYs) gained; and Abstinent Years). The reason being that different ICERs are more relevant to certain potential stakeholder groups than others.	30 days post randomization
Other	RCT Component: Cost effectiveness of XR-BUP compared to SL-BUP using ICER (incremental cost-effectiveness ratio): QALYs	The final outcome measure for the cost-effectiveness analysis is the ICER (incremental cost-effectiveness ratio), which includes the relevant cost differential between the study arms in the numerator, and the difference in a chosen effectiveness measure in the denominator. 3 types of ICERs will be generated, each one with a different effectiveness measure (engagement in formal addiction treatment at 30 days; quality-adjusted life-years (QALYs) gained; and Abstinent Years). The reason being that different ICERs are more relevant to certain potential stakeholder groups than others.	30 days post randomization
Other	RCT Component: Cost effectiveness of XR-BUP compared to SL-BUP using ICER (incremental cost-effectiveness ratio): Abstinent Years	The final outcome measure for the cost-effectiveness analysis is the ICER (incremental cost-effectiveness ratio), which includes the relevant cost differential between the study arms in the numerator, and the difference in a chosen effectiveness measure in the denominator. 3 types of ICERs will be generated, each one with a different effectiveness measure (engagement in formal addiction treatment at 30 days; quality-adjusted life-years (QALYs) gained; and Abstinent Years). The reason being that different ICERs are more relevant to certain potential stakeholder groups than others.	30 days post randomization
Primary	RCT Component: Patient engagement (yes/no) in formal addiction treatment at 7 days post randomization	Engagement in formal addiction treatment will be defined as enrollment and receiving formal addiction treatment on the 7th day post randomization, confirmed by contact with the facility and/or treating clinician. Formal addiction treatment will be operationally defined as those treatments consistent with the American Society of Addiction Medicine's levels of care (1-4) and can include a range of clinical settings including office-based providers of BUP or naltrexone, opioid treatment programs (OTPs), intensive outpatient, inpatient, or residential treatments. Patients do not need to be receiving MOUD at 7 days to be considered engaged in formal addiction treatment. Participation in a mutual-help program such as Alcoholics Anonymous (AA) or (Narcotics Anonymous) NA alone will not be considered as engagement in formal addiction treatment. Additional analyses evaluating the effects of patient and site characteristics will also be conducted.	7 days post randomization
Secondary	RCT Component: Engagement in MOUD (yes/no) at 7 days post randomization	self-report verified with treatment provider(s)	7 days post randomization
Secondary	RCT Component: Patient engagement (yes/no) in formal addiction treatment at 30 days post randomization	Engagement in formal addiction treatment will be defined as enrollment in formal addiction treatment on the 30th day post randomization, confirmed by direct contact with the facility and/or treating clinician. Formal addiction treatment will be operationally defined as those treatments consistent with the American Society of Addiction Medicine's levels of care (1-4) and can include a range of clinical settings including office-based providers of BUP or naltrexone, OTPs, intensive outpatient, inpatient, or residential treatments. Patients do not need to be receiving MOUD on the 30th day post randomization to be considered engaged in formal addiction treatment. Participation in a mutual-help program such as Alcoholics or Narcotics Anonymous alone will not be considered as engagement in formal addiction treatment. Additional analyses evaluating the effects of patient and site characteristics will also be conducted.	30 days post randomization
Secondary	RCT Component: Patient Engagement in MOUD (yes/no) at 30 days post randomization	self report verified with treatment provider(s)	30 days post randomization
Secondary	RCT Component: Self-reported days of illicit opioid use (past 7 days) at 7 days post randomization	The Timeline Follow-back procedure will be used to elicit the patient participant's self-reported days of use of opioids.	7 days post randomization
Secondary	RCT Component: Self-reported days of illicit opioid use (past 7 days) at 30 days post randomization	The Timeline Follow-back procedure will be used to elicit the patient participant's self-reported days of use of opioids.	30 days post randomization
Secondary	RCT Component: Craving scores at 7 days post randomization	The investigators will use visual analogue scales (VAS) to assess craving, desire to use opioids and need to use opioids with a scale of 0-100.	7 days post randomization
Secondary	RCT Component: Healthcare services utilization (past 30 days) regarding ED visits and hospitalizations at 30 days post randomization	A brief, structured interview regarding health care utilization (inpatient and outpatient) will be used, which collects information on the type and amount of services received. This includes ED visits, hospitalizations, primary medical care visits (excluding those for BUP treatment and self-help sources of support (e.g., NA).	30 days post randomization
Secondary	RCT Component: Patient satisfaction with BUP at 7 days post randomization	The investigators will modify the patient satisfaction scale where overall experience is rated from 1 to 5 (1 is completely ineffective and 5 is completely effective) and treatment characteristics are rated 1 to 7 (1 is not important and 7 is extremely important) based on previous published data.	7 days post randomization
Secondary	RCT Component: Overdose Events at 30 days post randomization	Assessment of past 30-day overdose events will be completed at 30 days post study enrollment. In addition, Site PIs will search local electronic medical records for fatal and non-fatal overdose events.	30 days post randomization
Secondary	Ancillary Component: Proportion of participants that experience a 5 or greater increase in COWS score within 4 hours of of XR-BUP administration	Clinical Opiate Withdrawal Scale (COWS) - the COWS is a validated measure of the severity of opioid withdrawal that consists of 11 subjective and objective items. Scores on the individual items are combined to a single overall score that has been used to determine the SL-BUP induction strategy. COWS scoring, and interpretation is as follows: Score: 5-12 = mild opioid withdrawal; 13-24 = moderate opioid withdrawal; 25-36 = moderately severe opioid withdrawal; more than 36 = severe opioid withdrawal.	Within 4 hours of XR-BUP administration
Secondary	Ancillary Component: Proportion of participants that transition to moderate withdrawal (COWS 13-24) within 4 hours of XR-BUP administration	Clinical Opiate Withdrawal Scale (COWS) - the COWS is a validated measure of the severity of opioid withdrawal that consists of 11 subjective and objective items. Scores on the individual items are combined to a single overall score that has been used to determine the SL-BUP induction strategy. COWS scoring, and interpretation is as follows: Score: 5-12 = mild opioid withdrawal; 13-24 = moderate opioid withdrawal; 25-36 = moderately severe opioid withdrawal; more than 36 = severe opioid withdrawal.	Within 4 hours of XR-BUP administration
Secondary	Ancillary Component: Proportion of participants that experience clinician determined precipitated withdrawal within 1 hour of XR-BUP administration	Assessment of Proportion of participants that experience clinician determined precipitated withdrawal within 1 hour of XR-BUP administration.	Within 1 hour post XR-BUP injection